DEA telehealth rules let you prescribe Schedule II to V controlled substances without an in-person exam only through December 31, 2026. The fourth temporary rule from DEA and HHS took effect January 1, 2026. As of November 14, 2026, no fifth extension has been published and the permanent rule is still under White House review.
What changed
One thing changed on January 1, 2026: the date. The fourth temporary rule republished 21 CFR 1307.41 and 42 CFR 12.1 with December 31, 2026 in place of December 31, 2025.
| Telehealth prescribing authority | Third temporary rule | Fourth temporary rule |
|---|---|---|
| Authorization expires | December 31, 2025 | December 31, 2026 |
| Published in the Federal Register | November 19, 2024 | December 31, 2025 |
| Schedules covered | II to V | II to V, unchanged |
| Prior in-person evaluation | Not required | Not required |
| Regulations amended | 21 CFR 1307.41, 42 CFR 12.1 | Same two sections, republished |
| Citation | 89 FR 91253 | 90 FR 61301 |
The agencies skipped notice and comment to avoid what they call the telemedicine cliff: the return of the Ryan Haight Act in-person requirement on January 1, 2026. Of roughly 44.6 million controlled substance prescriptions written across 258 organizations in 2024, more than 7 million, about 16 percent, went to patients never evaluated in person.
Who is affected
Every DEA-registered practitioner who prescribes controlled substances remotely. The rule names no specialty and carves out no schedule. Physicians, PAs, and nurse practitioners with prescribing authority sit under the same four conditions.
- A legitimate medical purpose, in the usual course of professional practice.
- An interactive telecommunications system as described at 42 CFR 410.78(a)(3).
- A DEA registration covering that class of drug, or an exemption under 21 U.S.C. 822(d).
- Every other requirement of 21 CFR part 1306.
Two final rules took effect December 31, 2025 and run alongside this one: buprenorphine via telemedicine, and continuity of care for Veterans Affairs patients. Both carry heavier conditions, so a practitioner covered by either may still use the temporary rule.
What the DEA telehealth rules do not change
Federal permission is not state permission. HHS said plainly that the extension leaves untouched the requirement that prescriptions comply with federal and state law. Where a state rule is stricter, the state rule binds you.
Two states make the gap obvious. Alabama permits a controlled substance prescription by telehealth only if the prescriber has had at least one in-person encounter with that patient in the preceding 12 months, on synchronous audio or video (Ala. Code 34-24-703 and 34-24-704). Arkansas is tighter still: its Medical Board rule bars a physician from prescribing any Schedule II through V drug by telemedicine unless the patient has been seen in person, or a relationship exists through consultation, referral, on-call or cross-coverage, or ongoing care. The Center for Connected Health Policy tracks the rule state by state (accessed November 14, 2026).
Common mistake: reading the federal extension as national permission. A prescriber in Arkansas who relies on it, with no in-person exam and no qualifying relationship, is square with DEA and crosswise with the board that holds the license.
Licensure sits outside the rule as well: state boards decide whether you may treat across state lines at all, and most expect a license where the patient is located.
Deadlines: what happens after December 31, 2026
The authorization ends at the close of December 31, 2026. The rule has no grace period and nothing rolls over on its own. Unless DEA publishes permanent regulations or a fifth extension before then, the Ryan Haight in-person evaluation requirement applies again from January 1, 2027.
The permanent framework is close but not public. DEA proposed Special Registrations for Telemedicine on January 17, 2025, drew more than 6,475 comments, and on August 25, 2026 sent a final rule to OIRA, the White House office that clears significant regulations. OIRA still lists it as pending review, and the federal regulatory agenda gives November 2026 for final action. As of November 14, 2026, the Federal Register shows no final rule and no fifth extension.
Pressure for a stopgap is public. On November 2, 2026, a coalition convened by the Alliance for Connected Care asked DEA for a fifth extension through at least December 31, 2027. None has been published.
Deadline watch: the fourth rule reached public inspection on December 30, 2025, one day before the third expired. With a final rule at OIRA, the next change may arrive just as late, and it may replace the flexibilities rather than extend them. In our experience, the practices caught out treat a temporary rule as settled policy.
What to do now
Your DEA registration does not change because of this rule. Plan as if nothing arrives before December 31, 2026, and adjust if it does.
- Diary the date and watch the Federal Register. A final rule or a fifth extension appears there first.
- List the patients at risk. Flag everyone on a controlled substance whom you have never examined in person, and decide who needs an in-person evaluation before January 1, 2027 if the rule lapses.
- Check the state, not just the schedule. Run every state where your patients sit against its board rule, whether that means an Alabama medical license or a state that layers its own paperwork on top of your federal DEA registration.
- Confirm both clocks. DEA registration renews on its own three-year cycle, separate from your license (see the questions physicians ask at renewal), and renewing registrants still attest to the one-time eight-hour MATE Act training.
- Document the four conditions in the chart, not only in the platform log.
Frequently asked questions
Can telehealth prescribe controlled substances?
Yes, through December 31, 2026. A DEA-registered practitioner may prescribe Schedule II to V controlled substances after a telemedicine encounter with no prior in-person exam, provided the prescription meets the four conditions in 21 CFR 1307.41. State law may still require an in-person visit.
Can doctors prescribe controlled substances online?
Only inside the federal telemedicine framework. The encounter needs an interactive telecommunications system, the prescription needs a legitimate medical purpose in the usual course of practice, and the prescriber needs a DEA registration covering that drug class.
Do I need a DEA registration for telemedicine?
Yes. The temporary rule waives the in-person evaluation, not the registration. You need a DEA registration authorizing the schedule you are prescribing, or an exemption under 21 U.S.C. 822(d). Some states add a state controlled substance registration on top of the federal one.
The Bottom Line
Nothing about your prescribing changed on January 1, 2026, and all of it may change on January 1, 2027. The permanent rule is in final White House review with no text public, and the rule that restricts most prescribers today is still the one their own state board wrote.
Our team handles DEA registrations, state controlled substance registrations, and medical licenses in all 50 states, from application through board approval. We work with physicians, PAs, and nurse practitioners.
This article provides general guidance only. Telemedicine prescribing rules change frequently and vary by state. Always verify current requirements with DEA and your state medical board before prescribing a controlled substance remotely. Last fact-checked: November 14, 2026.
Written by Medicallicensing Team · Reviewed by David Ivaniuk, CEO Medicallicensing · Last updated: November 14, 2026 · Last fact-checked: November 14, 2026
